Sign In
Buy MMIRF
$0.0130
+0 (+0%)
At Close: Jul 31, 2026
MedMira receives Health Canada approval for its Multiplo(R) Rapid (TP/HIV) Test for Syphilis and HIV
12:00pm, Tuesday, 24'th Dec 2024
HALIFAX, NS / ACCESSWIRE / December 24, 2024 / MedMira Inc. (MedMira) (TSXV:MIR) announced today that it has received today, on December 24, 2024, the approval from Health Canada for its Multiplo® Ra
MedMira Reports FY2024 Fourth Quarter and Year End Financial Results
11:00pm, Thursday, 28'th Nov 2024
HALIFAX, NS / ACCESSWIRE / November 28, 2024 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the financial year ended July 31, 2024. Corporate Update In December 2023,
MedMira Announces the appointment of Vice President of Commercial Operations
07:00pm, Thursday, 03'rd Oct 2024
MedMira Inc. continues its North-American expansion plan HALIFAX, NS / ACCESSWIRE / October 3, 2024 / Today, MedMira Inc. (MedMira) (TSXV:MIR) today announced the appointment of Nicole Crenshaw as Vic
MedMira Reports Third Quarter Results FY2024
11:00pm, Tuesday, 02'nd Jul 2024
HALIFAX, NS / ACCESSWIRE / July 2, 2024 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the quarter ended April 30, 2024. Corporate update In Q3 FY2024, MedMira focuse
MedMira Announces the Hire of Vice President of Business Development
10:00pm, Tuesday, 30'th Apr 2024
HALIFAX, NS / ACCESSWIRE / April 30, 2024 / Today, MedMira Inc. (MedMira) (TSXV:MIR) is pleased to announce the expansion of their commercialisation team by welcoming Ms. Rene Bell to the position of
MedMira Reports Second Quarter Results FY2024
10:30pm, Monday, 01'st Apr 2024
HALIFAX, NS / ACCESSWIRE / April 1, 2024 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the quarter ended January 31, 2024. Corporate update During Q2 FY2024, MedMira
MedMira Receives Canadian Patent for its Unique Quantitative Diagnostic System
04:30pm, Wednesday, 13'th Mar 2024
HALIFAX, NS / ACCESSWIRE / March 13, 2024 / Today, MedMira Inc. (MedMira) (TSXV:MIR) announces the receipt of a Canadian patent patent (number 2,949,634) for its new innovative and quantitative test s
CORRECTION BY SOURCE: Corporate Update on Clinical Evaluation of MedMira's Products
08:10am, Thursday, 01'st Feb 2024
Correction: Extended clarification. HALIFAX, NS / ACCESSWIRE / February 1, 2024 / Today, MedMira Inc. (MedMira) (TSXV:MIR) is pleased to provide an update on the ongoing review process by Health Canad
Corporate Update on Clinical Evaluation of MedMira's Products
07:35am, Thursday, 01'st Feb 2024
HALIFAX, NS / ACCESSWIRE / February 1, 2024 / Today, MedMira Inc. (MedMira) (TSXV:MIR) is pleased to provide an update on the ongoing review process by Health Canada. The Company made the required sub
MedMira Reports First Quarter Results FY2024
11:00pm, Friday, 29'th Dec 2023
HALIFAX, NS / ACCESSWIRE / December 29, 2023 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the quarter ended October 31, 2023. Corporate update During Q1 FY2024, Med
U.S. FDA Approves MedMira's Advanced Reveal G4 Rapid HIV-1/2 Antibody Test
10:30pm, Wednesday, 13'th Dec 2023
HALIFAX, NOVA SCOTIA / ACCESSWIRE / December 13, 2023 / MedMira Inc. (MedMira) (TSXV:MIR) proudly announces today the successful attainment of 510(k) clearance for the HIV-2 claim on the Reveal® G4 R
MedMira Reports FY2023 Fourth Quarter and Year End Financial Results
11:00pm, Tuesday, 28'th Nov 2023
HALIFAX, NS / ACCESSWIRE / November 28, 2023 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the financial year ended July 31, 2023. Corporate Update Throughout the re
Update on MedMira's Regulatory Path in Canada and the USA
10:00pm, Wednesday, 27'th Sep 2023
HALIFAX, NS / ACCESSWIRE / September 27, 2023 / Today, MedMira Inc. (MedMira) (TSXV:MIR) provides an update on its progress to achieve regulatory approval in Canada and the USA for its infectious dise
MedMira Reveal Rapid HIV-1 Antibody Test
07:35pm, Monday, 28'th Feb 2022 US Food and Drug Administration
Detection of antibodies to HIV-1 in human serum or plasma specimens
MedMira Reveal G2 Rapid HIV-1 Antibody Test
07:29pm, Monday, 28'th Feb 2022 US Food and Drug Administration
To allow for the addition of a procedural and reagent control line, a change in the packaging of the Colorimetric Detection Agent, and a change in the name of the device to Reveal TM G2 Rapid HIV-1 Antibody Test
